Epizyme Inc EPZM:NASDAQ

Last Price$1.47Cboe Real-Time Last Sale as of 9:39AM ET 6/30/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change0.00(0.00%)
Bid (Size)$1.46 (30,820)
Ask (Size)$1.47 (5,900)
Day Low / High$1.47 - 1.47
Volume29.9 K
  • Latest Stories
  • Commentary and Analysis
--Cowen Downgrades Epizyme to Market Perform From Outperform; Price Target is $1.50
5:12AM ET 6/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Sector Update: Health Care Stocks Mixed Pre-Bell Monday
9:25AM ET 6/27/2022 MT Newswires

Health care stocks were mixed pre-bell Monday. The Health Care SPDR (XLV) was up 0.12%, and the iShares NASDAQ Biotechnology Index (IBB) was recently 0.20%...

Wall Street Set for Positive Open, Extending Gains on Easing Inflation Expectations
9:20AM ET 6/27/2022 MT Newswires

US stocks were set for narrow gains Monday, extending previous session's gains after an inflation expectation gauge showed a slight easing. Dow Jones...

Wedbush Cuts Epizyme to Neutral From Outperform, Price Target to $1.45 From $7, Citing Ipsen Offer
8:23AM ET 6/27/2022 MT Newswires

Epizyme (EPZM) has an average rating of buy and price targets ranging from $0.60 to $8, according to analysts polled by Capital IQ. (MT Newswires covers...

Top Premarket Gainers
8:01AM ET 6/27/2022 MT Newswires

Acutus Medical (AFIB) shares nearly doubled after the company launched an expanded suite of left-heart access products. Evofem Biosciences (EVFM) shares...

Epizyme Agrees to be Acquired by Ipsen for $247 Million
3:29AM ET 6/27/2022 MT Newswires

Epizyme (EPZM) has agreed to be acquired by French pharmaceutical company Ipsen for a total of $247 million, Ipsen said Monday. Under the terms, Ipsen's...

HC Wainwright Adjusts Epizyme's Price Target to $6 From $8, Reiterates Buy Rating
7:07AM ET 6/03/2022 MT Newswires

Epizyme (EPZM) has an average rating of outperform and price targets ranging from $0.60 to $8, according to analysts polled by Capital IQ. (MT Newswires...

HUTCHMED Secures Regulatory Clearance for Use of Oncology Drug Tazverik in China's Hainan Medical Tourism Pilot Zone
5:02AM ET 6/01/2022 MT Newswires

HUTCHMED (HCM) said Wednesday that the Health Commission and Medical Products Administration of Hainan Province has approved the use of Tazverik within the...

--HC Wainwright Adjusts Epizyme Price Target to $8 From $10, Maintains Buy Rating
10:48AM ET 5/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Adjusts Price Target for Epizyme to $7 From $9, Maintains Outperform Rating
3:17PM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...